Company profile: Adalvo
1.1 - Company Overview
Company description
- Provider of B2B pharmaceutical products and services, part of Alvogen Group and powered by Alvogen and Alvotech. Offers 90+ specialty generic small-molecule products across Oncology, Women’s Health, Cardiovascular and CNS; 15+ value-added 505(b)(2) CNS therapies; and 8+ peptide products for Rare Diseases and Diabetes. Develops Fidaxomicin 200 mg tablets, Ethinylestradiol/Drospirenone, and Dimethyl Fumarate for RRMS.
Products and services
- Peptide Portfolio: Architects a peptide-based portfolio of over 8 products focused on treating Rare Diseases and Diabetes, supporting partner access to peptide therapeutics in these indications
- Specialty Gx Portfolio: Produces a small-molecule portfolio of over 90 products across Oncology, Women’s Health, Cardiovascular, and CNS therapeutic classes for global partners seeking differentiated B2B pharmaceuticals
- Value Added (505(b)(2)) Portfolio: Develops a 505(b)(2)-pathway portfolio of over 15 value-added products primarily focused on Central Nervous System treatments, enabling partner access to differentiated therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Adalvo
Bioassay Online
HQ: Germany
Website
- Description: Provider of creation and implementation of bioanalytical assays in pharmacology, immunology, and toxicology, offering potency assay development; GMP validation, lot release testing, and stability studies; development and execution of potency assays for biologics, proteins, monoclonal antibodies, vaccines, gene therapies, and APIs; and efficacy models and safety assessments for biosimilars or APIs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioassay Online company profile →
TransCure BioServices
HQ: Switzerland
Website
- Description: Provider of predictive preclinical R&D services via fee-for-service access to humanized mouse platforms, including CD34+ humanized immune system, humanized liver, immuno-oncology, IBD, inflammatory disorder, and infectious disease (HIV, HBV) models, used to profile new drugs and assess efficacy/toxicity, drug-drug interactions, immunotherapies, and antivirals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TransCure BioServices company profile →
Biodextris
HQ: Canada
Website
- Description: Provider of analytical and process development, early-phase clinical manufacturing, packaging, and scalable bioproduction services for vaccines and biologics. Offers quality control testing and validation to ensure regulatory compliance, with tailored development solutions for biotech and pharmaceutical companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biodextris company profile →
S-Cubed
HQ: Denmark
Website
- Description: Provider of consultancy services, including biometrics, biostatistics, data, and visual analytics for pharmaceutical industries.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full S-Cubed company profile →
US Pharma Lab
HQ: United States
Website
- Description: Provider of custom development, manufacturing, and supply services for premium dietary supplement ingredients, premixes, and products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full US Pharma Lab company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Adalvo
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Adalvo
2.2 - Growth funds investing in similar companies to Adalvo
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Adalvo
4.2 - Public trading comparable groups for Adalvo
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →